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Background and Aim: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although fac-
tor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency 
in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study 
regarding the association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy. Materials and Me thods: The 
study consists of two groups: cancer patients with VTE were included as Group 1 (n = 46); Group 2 comprises 196 cancer patients 
without VTE. Restriction fragment length polymorphism method was used for the detection of polymorphisms of TF −603A/G in the 
5՛upstream region and TF 5466A/G in intron 2. FVL, PT G20210A and MTHFR C677T polymorphisms were determined by using 
commercially available Light Cycler kits. The genotype and allele frequencies between the groups were compared using χ2 or Fisher 
exact test, if appropriate. Results: No differences were observed in the distribution of TF gene −603A/G genotype frequencies between 
the groups. Although a slightly increased incidence of +5466GA genotype was in Group 1 (17.4% vs 11.2%), it did not achieve statisti-
cal significance. The prevalence of FVL was significantly greater in Group 1 compared with Group 2 (41.3% vs 4.1%, p < 0.05). Dif-
ference in frequency of 677TT+CT (MTHFR) + 5466GG (TF) genotypes combination was found in women of two investigated Groups 
(p < 0.05). No differences were also in genotypes and allele frequencies of MTHFR C677T and PT G20210A between two Groups 
(p > 0.05). Conclusions: The present study did not show significant association of TF gene −603A/G and +5466A>G polymorphisms 
with VTE in malignancy, however, further larger studies including different ethnic population are needed to confirm our findings.
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Venous throm�oem�olism �VTE� is one of the most 
common complications in cancer patients. VTE can 
�e seen in �5% of cancer patients during the progres-
sion of the disease [�]. Throm�osis is multifactorial; 
decreased native anti-coagulants� increased pro-
throm�otic factors and decreased fi�rinolysis can cause 
throm�osis progress [�]. Hereditary and acquired fac-
tors act a part in the progression of idiopathic VTE [�]. 
Factor V Leiden �FVL� is an important hereditary factor. 
Recent studies have shown that FVL mutation increased 
the risk of VTE in cancer patients as compared to cancer 
patients without VTE. Prothrom�in �PT� gene G�����A 
mutation plays also a significant role in VTE related 
events in cancer patients [4��].
Tissue factor �TF� or coagulation factor III is a 4� kDa 
single strand transmem�rane glycoprotein. It contains 
��� aminoacides and is expressed on the surface 
of various cells except from the vascular system [�]. 
TF activates coagulation factor VII and initiates the 
coagulation system �y activating factor VII. Bacterial 
lipopolysaccharides� various inflamatory cytokines� 
vascular lesions� cancer and sepsis caused �y gram 
negative �acteria can induce TF expression. This cau-
ses procoagulant activity and throm�us development 
�y the activation of TF pathway [�].
As a result of endothelial damage� su�endotelial 
matrix disclosure or direct stimulation of the endothe-
lium� are the most important stimuli for the activation 
of factors involved in hemostasis. TF expression is the 
most important event that develops after tissue da-
mage or endothelial activation. TF initiates throm�us 
formation �y turning inactive coagulation proteins into 
active factors. TF is also associated with microparticles. 
Microparticles carrying TF normally circulate in �lood. 
After vessel wall injury� they accumulate in the develo-
ping throm�us �y a P-selectin and P�GL-� dependent 
mechanism. Microparticles play a major role in the ge-
neration of fi�rin� TF and progression of throm�us [�� �].
Any change that will increase the expression 
of TF will result in more fi�rin formation and severe 
throm�us development. As the role of TF in throm�us 
pathophysiology �ecomes increasingly more impor-
tant and TF level is shown to increase in throm�osis 
related clinical conditions� TF gene polymorphisms are 
�rought on [�]. In this study� TF polymorphisms have 
�een investigated in cancer patients with and without 
VTE� and this is the first study on this su�ject.
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MATERIALS AND METHODS
In this study� two groups of patients were enrolled. 
Group � was composed of cancer patients with VTE 
�n = 4��. Group � was composed of cancer patients with-
out VTE �VTE didn’t develop during cancer therapy and 
the follow-up time� �n = ����. Informed consents of the 
patients were taken. The ethical committee of Yildirim 
Beyazit University Medical �chool has approved the 
study. The study was supported �y a grant from �cientific 
Research Project of Yildirim Beyazit University �project 
num�er: 5���.
DNA Isolation. Venous �lood samples from the pa-
tients and controls were analyzed using QIAamp® Blood 
Mini Kit �Qiagen�. DNA was purified on the QIAcu�e 
Instrument �Qiagen� Hilden� Germany�. The concentra-
tion of extracted DNAs was measured �y NanoDrop 
ND-���� �PeqLa�� �aveen Werner� �weden� and DNA 
was kept at −�� °C until analyzed.
Genotyping for TF 5466A>G polymorphism. 
Genotype of TF 54��A>G �rs�����4�� in intron 
� polymorphism was determined �y the polymerase 
chain reaction — restriction length fragment polymor-
phism �PCR — RFLP� method. This TF gene region 
surrounding +54��A>G polymorphism was amplified 
�y using 5՛ATG CAG TCA CTG TGC TGA GGA �՛ and 
5՛GGC AAA TTA CAG AGC CAT CC �՛ primer pair. PCR 
was run under standard conditions at annealing tem-
perature of 5� °C. The PCR products were digested 
�y HinfI �Fermentas UAB� Vilnius� Lithuania� restric-
tion endonuclease. Digested fragments were visual-
ized after ethidium �romide staining under UV light. 
Restriction fragments were separated �y �.5% 
agarose gel electrophoresis. Minor allele �+54��G� 
was expected to �e found mostly in a heterozygous 
form. Therefore� allele-specific HinfI restriction 
product lengths were either ���/�� �+54��A allele� 
or �4�/��/�� �ps �+54��A/G allele�.
Genotyping for TF −603A/G polymorphism. 
Genotype of TF −���A/G �rs �������� in the 5՛up-
stream region was also determined �y the poly-
merase chain reaction�restriction length fragment 
polymorphism �PCR — RFLP� method. Primer pair 
for amplifying this region was 5՛-CAT GAG AGA CAT 
CGC CTC TG-�՛ and 5՛-GAC CTA ACA TGT TCT AGC 
CAG AAG-�՛. PCR was run under standard conditions 
at annealing temperature of 5� °C. This procedure was 
followed �y Mva I restriction endonuclease digestion 
for �� h at �� °C and resolution �y electrophoresis 
on �.5% agarose gel. Digested fragments were visu-
alized after ethidium �romide staining under UV light. 
The resulting ��� �p PCR product was cleaved into two 
smaller fragments of �5� and ��� �p in the presence 
of a A nucleotide� � smaller fragments of ���; ��� and 
�4� �p in the presence of a G nucleotide� finally� four 
fragments of ��4; ���; �4�; �5� �p in the presence 
of A/G nucleotide.
To determine the genetic risk factors for th-
rom�ophilia� the su�jects were genotyped for FVL� 
factor II G�����A and C���T of MTHFR mutations 
�y PCR with Rotor Gene ���� LightCycler �Cor�ett Life 
�cience �cience� Concorde� N�W� according to the 
guidelines of the manufacturer.
Statistical analysis. The results were analyzed 
using �P�� programme. The genotype and allele 
frequencies �etween the groups were compared 
�y χ� or Fisher’s exact test� if appropriate.
RESULTS
TF polymorphisms were investigated in �4� pa-
tients �4� males� ��� females� for. The general data 
on the patients are shown in Ta�le �� and the frequen-
cies of the tumor types are listed in Ta�le �. In �oth 
groups �reast cancer is the most common type �with 
and without throm�osis�� while the testicular cancer 
is rare as well as thymoma.
Table 1. General patients’ data
Group 1 (n = 46) Group 2 (n=196)
Age (m ± SD) 57.0 ± 1.8 51.3 ± 0.9
Gender
Female 28 (60.9%) 165 (84.2%)
Male 18 (39.1%) 31 (15.8%)
Table 2. The frequencies of tumor types in study groups
Frequency %
Group 1
Lung 4 8.7
Brain 2 4.3
Liver 3 6.5
Colon 9 19.6
Breast 16 34.8
Stomach 5 10.9
Ovary 3 6.5
Sarcoma 3 6.5
Testis 1 2.2
Total 46 100.0
Group 2
Lung 19 9.7
Brain 4 2.0
Dermis 3 1.5
Tongue 2 1.0
Liver 1 0.5
Skeletal system 1 0.5
Colon 1 0.5
Larynx 1 0.5
Breast 152 77.6
Bladder 1 0.5
Nasopharynx 3 1.5
Lymphoma 2 1.0
Sarcoma 2 1.0
Testis 1 0.5
Tymoma 1 0.5
Uterus 2 1.0
Total 196 100.0
The prevalance of PT G������A and MTHFR C���T 
polymorphisms were similar in two groups �p > �.�5�. 
The allelic frequencies �etween two groups also 
also differed insignificantly. No difference was o�-
served in the distri�ution of TF gene −���A/G ge-
notype frequencies �etween the groups. Although 
a slightly increased incidence of +54�� GA genotype 
in Group � was o�served ���.4% vs ��.�%�� it did-
n’t achieve statistical significance. The prevalance 
of FVL was significantly higher in Group � compared 
with Group � �4�.�% vs 4.�%� p < �.�5� �Ta�le ��. The-
re was significant difference in Group � �etween the 
patients with TF 54�� polymorphism �homozygote/
heterozygote� and the patients with MTHFR C���T 
mutation �homozygote/heterozygote� �p < �.�5�. 
Except from this� there was no significant difference 
�etween the TF polymorphisms and throm�ophylia 
factors.
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There were significant differences in the num�er 
of women and men in Group � and Group �. �o� we also 
analysed separately the data for the groups �y gender. 
There were �� and ��5 women in Groups � and �� 
respectively. The prevalance of FVL was significantly 
higher in su�group � compared with su�group � ���.�% 
vs 4.�%� p < �.�5�. In su�group �� there was significant 
difference �etween TF 54�� polymorphism �homozygo-
te/heterozygote� and MTHFR C���T mutation �homozy-
gote/heterozygote� �p < �.�5�. Except from this� there 
was no significant difference �etween the TF polymor-
phisms in female patients and throm�ophilia factors. 
There were no differences in the prevalence of all geno-
types com�inations in patients of studied groups except 
significantly higher prevalence of ���TT+CT �MTHFR� 
+54��GG �TF� genotypes com�inations in women with 
VTE �su�group � ���.�%�� compared to women without 
VTE �su�roup � ���.�%�� �p < �.�5�.
Table 3. The frequencies of FVL, PT G201210A, MTHFR 
C677T and TF gene −603A/G and +5466 A>G polymorphisms 
in Group 1 and Group 2 (*p < 0,05)
Group 1 (n = 46) Group 2 (n = 196) p value
FVL
AA or GA 19 (41.3%) 8 (4.1%)
GG 27 (58.7%) 188 (95.9%) 0.05*
PT G20210A
AA or GA 3 (6.5%) 8 (4.1%)
GG 43 (93.5%) 188 (95.9%) 0.442
MTHFR C677T
TT 2 (4.3%) 16 (8.2%)
CT 21 (45.7%) 80 (40.8%) 0.623
CC 39 (50.6%) 100 (51.0%)
TF −603A/G
GG or AG 31 (67.4%) 131 (66.8%)
AA (wild type) 15 (32.6%) 65 (33.2%) 0.943
TF +5466A>G
GG or AG 8 (17.4%) 23 (11.7%)
AA (wild type) 38 (82.6%) 173 (88.3%) 0.302
DISCUSSION
Recently� there have �een some studies re-
garding the association �etween TF ���A/G and 
+54��A/G polymorphisms and throm�osis in patients 
with heart attack [��]� �ut there has �een no pu�lished 
study related to the polymorphisms in cancer patients 
with throm�osis. The present study is the first one that 
determines the relationship �etween the TF polymor-
phisms� cancer and VTE.
Various types of hemostatic disorders along with 
different complications are present in cancer patients� 
in particular� coagulation a�normalities [��]. VTE is one 
the most common causes of death in cancer patients [��� 
��]. The VTE develops at nearly �5% of all cancer cases 
during the progression of the disease [�4� �5].
Previous studies indicated that the FVL mutation 
is mostly o�served in cancer patients with VTE com-
pared to patients without VTE in Turkish population [��� 
��]. In our recent study� there was also a higher frequ-
ency of FVL mutations in Group � compared to Group 
�. But� there was no statistical difference �etween the 
groups for MTHFR C���T and PT G�����A polymorp-
hisms.
In recent studies� there is no association �etween 
MTHFR C���T polymorphisms and some malignant 
tumors including �reast cancer and colorectal carcino-
ma [��� ��]. In our study� we investigated the relations-
hip �etween MTHFR C���T polymorphisms and VTE 
development and demonstrated no association �etwe-
en VTE risk and this polymorphism. However� Ozkan 
et al. [��] reported a significant difference �etween 
cancer patients with and without VTE for MTHFR C���T 
polymorphisms. We also found a significant difference 
�etween TF 54�� polmorphism and MTHFR C���T 
mutation in Group � �cancer patients without throm-
�osis�. �o� we suggest that the association of MTHFR 
C���T mutation and TF 54�� polymorphism is im-
portant and this must �e taken into consideration for 
cancer patients. Difference in frequency of ���TT+CT 
�MTHFR� + 54��GG �TF� genotypes com�ination was 
found in women �etween two investigated groups 
�p < �.�5�. Although there was a significant differen-
ce in the num�er of women and men in Group � and 
Group � �p < �.�5�� there was no effect of these gen-
der differences on the frequencies of polymophisms 
�etween the groups.
It is well known that PT G�����A mutation is rela-
ted to higher levels of PT causing increased throm�in 
formation. In some studies� it has �een reported that 
PT G�����A is an important factor in the development 
of VTE in cancer patients [4� �� ��]. On the contrary� 
some researchers reported no association �etween 
PT G������A and VTE risk in cancer patients [5� ��� ��� 
����4]. Our recent findings also support the su�ject.
Development of cancer-related throm�osis may 
�e associated with TF [�5]� expression of which can 
differ �etween tumor types. The VTE risk can �e related 
to high level of TF expression in cancer patients [��].
The development of TF is related closely with the 
transcription level of cellular specific promotor genes. 
The first study on this su�ject was pu�lished �y Arnaud 
et al. [��]. The promoter region of TF gene was inves-
tigated and six different polymorphisms �−����C/T� 
−�44�G/C� −����C/T� −����D/I� −���A/G� −��C/T� 
were identified. Conflicting results were pu�lished on the 
relationship �etween arterial or venous throm�osis and 
TF promoter region polymorphisms [��]. There are 
a few studies on throm�osis and TF −���A/G polymor-
phism. For the first time� Oti et al. [��] have reported that 
TF plasma levels were higher in patients with TF −���GG 
genotype. The authors also showed that the patients with 
this genotype had an increased heart attack risk.
In our study� we determined no significant as-
sociation �etween the development of throm�o-
sis and ���A/G and +54��A>G polymorphisms 
of TF in cancer patients. Although the frequency of 
+54�� GA genotype was higher in Group � according 
to Group � ���.4���.�%�� there was no statistically 
significant difference �p > �.�5�.
In conclusion� we have determined that FVL mu-
tation is an important risk factor for VTE development 
in cancer patients. However we did not find significant 
association of TF gene −���A/G and +54��A>G poly-
morphisms with VTE in malignancy. It can �e sugges-
ted that further larger studies including different ethnic 
��� Experimental Oncology ��� �������� ���� ��eptem�er�
populations and specific cancer types are needed 
to confirm our findings.
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